"PMID","tsneClusterNames","sentence","clustSummary"
"50e8d64761dddc0b7ce037734d813eca7cd63701","bat-speci","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.....respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.....the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).....however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .....a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 ."
"2bc8716c8d60412f241f096246127275b734635b","bat-speci","respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.....respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.....the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).....however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .....a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 ."
"550494d6d01569a05a8ca2d75f892486b01d1865","bat-speci","the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.....respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.....the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).....however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .....a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 ."
"0d5f9dd2c1626d1d3a4228b838fc0bc666363a3c","bat-speci","however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.....respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.....the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).....however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .....a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 ."
"87bfa13221ccf5a02d4a888ef1320b57f2c2d5e2","bat-speci","a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 .","how- ever, a relatively high prevalence of cov rna was detected in bats of 2 species collected at several different sites: 12% for big brown bats and 8% for long-legged bats, and at lower prevalence, 3% in little brown bats and 2% in western long-eared bats.....respondents were able to indicate significantly more threats to bats t (24) =´2.916, p = 0.008, more ways that they could help bats t (24) =´5.308, p < 0.001, and more ways in which bats benefit the environment t (24) =´6.245, p < 0.001 after attending the great lakes bat festival.....the highest prevalence of 65% (24/37) was observed for bat gammaherpesvirus 6 (batghv6) in common pipistrelle bats (p. pipistrellus), followed by bat gammaherpesvirus 5 (batghv5, 42.1%) in nathusius' pipistrelle bats (p. nathusii) and bat gammaherpesvirus 4 (batghv4, 33.8%) in noctule bats (n. noctula).....however, studies from wild or experimental bats indicate that most of these lethal viruses in humans and other mammals cause only asymptomatic infection in bats, suggesting a potentially special immune system in bats that is different from most other mammals [16, 17] .....a large number of novel bat virus sequences 24 was identified in these two bat suborders, which diverged over 50 million years ago, suggesting a 25 long co-evolutionary history of bats and their viruses that have shaped unique host-pathogen 26 relationships 19 ."
"33f0a6576216e3c8ff02dcb1affaa66c9f08e30b","ifn-respons","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .....mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .....moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.....nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.....interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus."
"38aa050ad79d8a1d7022c33535255ce9d47914e5","ifn-respons","mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .....mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .....moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.....nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.....interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus."
"da26991502da97b746b148ad17cb2b435ef8e0cb","ifn-respons","moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .....mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .....moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.....nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.....interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus."
"ac6b3fe26ffb1e6b3b34200c9053a724e81f2d7a","ifn-respons","nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .....mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .....moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.....nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.....interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus."
"2544d85288aa39f592b1e172f8c62040bc1b2ba6","ifn-respons","interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus.","ifn-γ has antiviral activity, but the most important effects of ifn-γ seem to be activation of macro-phages, antigen-presenting cells, and nk cells and inhibition of t-helper type 2 (th2) cells, resulting in a th1driven cell-mediated response to infection  .....mef cells were treated with mouse ifn-b at 1, 10, 50 or 100 u/ ml for 16 hrs before and after virus infection, meanwhile vero cells and a549 cells were treated with human ifn-a, ifn-b or ifn-c for 16 hrs before and after infection at 125, 250, 500 or 1000 u/ml (fig 1) .....moreover, the effect of type i ifn against hpev1 was inconsistent between a549 and t84 cells in that type i ifn pretreatment inhibited hpev1 infection in a549 but not t84 cells perhaps because of the lower sensitivity of type i ifn signaling in t84 cells.....nevertheless, the results obtained for rig-i, ifn-1, ifn-2/3, and ip-10 clearly demonstrate that dd778 can boost the innate immune response in virus-infected cells, in particular the expression of type iii ifns, which were produced at high levels in this system.....interestingly, we observed a significant increase of ifn-␤ mrna in cells infected with nh/p68 from 4 to 16 hpi, indicating that cellular signaling leading to ifn-␤ transcription is activated during the course of the infection with the attenuated virus."
"33bf14aff364a7ce589e97d8021006f940b1f899","mer-respiratori","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .....as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).....of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).....as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .....the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers."
"e68b0f3da8a02a8f0b86869e533eaf549f70ff9a","mer-respiratori","as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .....as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).....of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).....as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .....the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers."
"a4f120c79ea75052176f2c3d6a351485862a6ca8","mer-respiratori","of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .....as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).....of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).....as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .....the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers."
"dc180c51f54487e4bbbd129c1cc2e30deacd3181","mer-respiratori","as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .....as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).....of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).....as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .....the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers."
"03f315449023c980e42af7eb150d0cd9cab57f5a","mer-respiratori","the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers.","in the case of mers, the r 0 is currently less than 1 (most likely 0.5), indicating that mers-cov infection will inevitably die out; however, it is recommended, in such cases, to take into account the demographic stochasticity of mers-cov transmission (7) .....as of 27 november 2018, the world health organization (who) reported 2266 laboratory-confirmed cases of infection with mers-cov and 804 mers-associated deaths (about 36% fatality rate) in 27 countries (available online: http://www.who.int/emergencies/mers-cov/en/).....of the three mabs, m336 neutralized both pseudovirus and live mers-cov infectivity in cells with exceptional potency (m336 inhibited 90% mers-cov pseudovirus infection at a concentration of 0.039 g/ml, and neutralized live mers-cov with ic 95 of 1 g/ml and ic 50 of 0.07 g/ml).....as of june 2017, the world health organization (who) has been notified of 2037 laboratory-confirmed cases of infection with mers-cov and at least 710 deaths related to mers-cov, showing a much higher fatality rate (about 35%)  compared to sars-cov (less than 10%) [2, 3] .....the very high seroprevalence detected in camels warrants the initiation of an active surveillance study for mers cov in humans, particularly those that are at higher risks of exposure to mers-cov infections such as camel traders and abattoir workers."
"71cb2319da3251ef1b4bc99ce5c4ca633b2cb1b9","health-diseas","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.....some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .....health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.....in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .....the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015."
"77779295f3fcc05a193b349478b8730b226790c7","health-diseas","some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.....some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .....health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.....in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .....the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015."
"2d2b70166db15be7908f748930e9c56a300e5851","health-diseas","health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.....some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .....health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.....in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .....the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015."
"edca7aed5e25c0b8888f93a5f78ce0a1b27ed1d7","health-diseas","in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.....some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .....health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.....in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .....the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015."
"78c82f8e3198d5c95cbbcceabefddbe82e8f2442","health-diseas","the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015.","in order to better understand the fundamental concept of public health, we drew up a table of the categories used by the québec public health program and compared them to those of the who, the pan american health organization and the national public health.....some authors described the field of public health as multidisciplinary, high-benefit, but undervalued and that researchers and practitioners need to influence the development of public health research within individual countries to promote public health research area  .....health had its own commissioner, its own opportunity to protect itself and public health benefits."" (#15, public health advisor/advocate) on the other hand, aspects of failure were mentioned regarding the detachment of health and social policy at eu-level.....in 2015, data from these studies were used during a one health zoonotic disease prioritization workshop in kenya, where q-fever was identified as one of the diseases that would benefit from integrated prevention and control programs using the one health approach  .....the prioritization of zoonotic diseases was carried out through a facilitated consultative process involving 36 experts in zoonoses from the public health (n = 19), animal health (n = 15) and wildlife health (n = 2), during a three day workshop in september 2015."
"84dc4e9ee5f8dd324d2d436d7c07c7d0044a58a4","dog-anim","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.....four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.....reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).....antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).....antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 )."
"9ddb63e47ae59fb8d315bfe119d9a1a3426af592","dog-anim","four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.....four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.....reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).....antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).....antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 )."
"0036b28fddf7e93da0970303672934ea2f9944e7","dog-anim","reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.....four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.....reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).....antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).....antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 )."
"31a744d5cdf4b8901ea26a847bbc3cc76d6e02d7","dog-anim","antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.....four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.....reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).....antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).....antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 )."
"31a744d5cdf4b8901ea26a847bbc3cc76d6e02d7","dog-anim","antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 ).","elevation of ctni (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; iqr 0.59-7.56 ng/ml; normal <0.06 ng/ml) and cr (dog 1: 2.7 mg/dl; dog 2: 4.3 mg/dl; dog 3: 15.5 mg/dl; dog 4: 3.8 mg/dl; dog 5: 7 mg/dl; median 4.3 mg/dl; iqr 3.8-7 mg/dl; normal 0.7-1.2 mg/dl;) was detected in all dogs.....four of these dogs were classified as puppies; three dogs were from the crcov n (% dogs) 95% ci 16 (7.5) 4.0 -11.0 9 (5.2) 1.9 -8.5 7 (17.0) 5.6 -28.6 2 (4.0) 0.0 -9.4 cpiv n (% dogs) 95% ci 14 (6.5) 3.2 to 9.9 11 (6.4) 2.7 to 10. adolescent subgroup and seven dogs were adults.....reference ranges (5-95th percentile) for left adrenal gland maximum thickness were as follows: 3.4-4.8 mm (dogs ≥2.5-5 kg), 3.4-5.6 mm (dogs >5-10 kg), 3.9-6.2 mm (dogs >10-20 kg), and 5.2-7.4 mm (dogs >20-40 kg); whereas for right adrenal gland maximum thickness were as follows: 3.2-5.5 mm (dogs ≥2.5-5 kg), 3.8-6.0 mm (dogs >5-10 kg), 4.2-7.7 mm (dogs >10-20 kg), and 5.4-9.4 mm (dogs >20-40 kg).....antibodies against cpv were detected in 20% of the animals aged less than 6 months (2/10), in 57.1% in dogs aged between 6 months and 1 year (8/14), in 87.5% in dogs with 1 to 2 years (14/16), in 85.3% in dogs with 2 to 5 years (29/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years ( figure 1 ).....antibodies against cdv were detected in 30% of animals aged less than 6 months (3/10), in 50% of dogs aged between 6 months and 1 year (7/14), in 56.3% of dogs with 1 to 2 years (9/16), in 53% of dogs with 2 to 5 years (18/34), in 75% in dogs with 5 to 7 years (6/8) and in 1/1 dog older than 7 years (2011 samples) ( figure 2 )."
"09d2a697632210efee7bf9fe6ee07b66bb7248f2","cell-hiv","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .....for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.....their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .....it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.....the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig."
"1adab26eb1167a39014dc503174f7d34f9087664","cell-hiv","for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .....for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.....their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .....it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.....the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig."
"09d2a697632210efee7bf9fe6ee07b66bb7248f2","cell-hiv","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .....for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.....their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .....it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.....the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig."
"f02529d9be6c7576b60d295c4e04d15a9a432614","cell-hiv","it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .....for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.....their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .....it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.....the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig."
"f02529d9be6c7576b60d295c4e04d15a9a432614","cell-hiv","the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig.","their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multinucleated cells    .....for hiv-1 infection, jurkat cells (clone je6.1) were seeded at 2ˆ10 5 cells/ml for 24 h, and infected with known amounts of hiv-1 (hiv-1 mn strain, 10 9 copies per 10 6 cells) for 2 h, washed twice with pbs, and cultured for periods of time indicated.....their antiretroviral activity is manifested through an alteration of the interaction between hiv gp120 or gp41 and the corresponding receptors  , which, in the end, inhibit the hiv cell function, hiv infectivity, and the formation of the syncytium, multi-nucleated cells    .....it is thus possible that the superiority of hiv-1 nl4-3 over hiv-1 bh10 in replicating in ifitm1expression supt1 cells, despite that both viruses are equally impaired by ifitm1 in the oneround infection, might be a result of the greater ability of hiv-1 nl4-3 to transmit between cells.....the results of infection experiments showed that hiv-1 nl4-3 env enabled hiv-1 bh10 to replicate in ifitm1-expressing cells, whereas inserting the env of hiv-1 bh10 into hiv-1 nl4-3 dramatically reduced virus replication in the presence of ifitm1 (fig."
"c8d206a4f9af0709b6e9ee90c4d854d482cb0784","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"a9c58042555c0d56b8e94bc5558db0c3dd697dcc","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"99a46ba28f5811c112876ec77f570d6c10778db6","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"c672f5b0d7c0a40f7cc1bdf079066d72eb8f64ec","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"e046a06f262d74d025272ad697d358c4afb5d9bd","coronaviru-china","cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"734779fad93249a2f6fede6afd10eeff7b37919b","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"10525ac89e46be4cb9cb9fd1131d28411a902047","coronaviru-china","cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"10525ac89e46be4cb9cb9fd1131d28411a902047","coronaviru-china","cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"9c33486a49de4aea64ce61c0a2c21a88c316b6a8","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"38bab3f17b186bd8ee289e5d135bb7d500ef500b","coronaviru-china","cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"4f8d24c531d2c334969e09e4b5aed66dcc925c4b","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"e066fdbb4a9338a57477424cb66fd4d75b2fd66d","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"10525ac89e46be4cb9cb9fd1131d28411a902047","coronaviru-china","cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"5d3612cd95331a2f0c43ef9d03ce583b5ff8c995","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"ea17aad7692bb5040f3b2ba1d01b8249e4969469","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"f19e2df932f90f387fe71533f3802875d9042160","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"fbebe4b66073c44cface2e842754bce26e3e2913","coronaviru-china","cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"0ff4ad5359ee2df3568605385a8616d8da66bf2c","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"fbc41a8e025cd6eb2d7c156aad3b6923af2349c4","coronaviru-china","cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"af266fac8970a7960e96630a67d91bec5dda0335","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"8762adc9311e5803d1de438493772269acfe7fa3","coronaviru-china","cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"0562f70516579d557cd1486000bb7aac5ccec2a1","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"090b6c8b3df30bc248221869f673a2d970caa1b9","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"dcd7a1235ea74e3ef71d051103bf8a64c3c8f457","coronaviru-china","cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"1ad1d4b84aea4ceaf05c62a1ad04e7150f7f4684","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"ca88735399ff43d0e673876200655099f06f5567","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"0fd300aefb704c20f32152b97b6194015f1c74e7","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"ae6fc64042b050df93ebb8f8045892952f18510f","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"1ad1d4b84aea4ceaf05c62a1ad04e7150f7f4684","coronaviru-china","cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint","cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20025643 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.23.20026856 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026682 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.12.20022418 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.25.20027755 doi: medrxiv preprint 1 .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20031112 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.28.20029181 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.03.20030627 doi: medrxiv preprint .....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.13.20020891 doi: medrxiv preprint 2,077 cases.....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.22.20024927 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.04.20030965 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19011940 doi: medrxiv preprint q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q  .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.03.20020206 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.06.20032334 doi: medrxiv preprint 181 .....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.01.20029074 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.16.20023838 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.01.30.20019877 doi: medrxiv preprint  .....cc-by-nc 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.11.20022228 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.05.20031815 doi: medrxiv preprint....cc-by-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.05.20020792 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029348 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/19008417 doi: medrxiv preprint....cc-by 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.09.20021477 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint  number of cases .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.03.09.20033183 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20026773 doi: medrxiv preprint .....cc-by-nc-nd 4.0 international license it is made available under a author/funder, who has granted medrxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.20.20025973 doi: medrxiv preprint....cc-by-nc-nd 4.0 international license it is made available under a is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. (which was not peer-reviewed) the copyright holder for this preprint . https://doi.org/10.1101/2020.02.29.20029462 doi: medrxiv preprint"
"8d095d0275e474dbb9d9b63a75591ff2c0667d73","hrv-human","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .....38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.....the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).....in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).....analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below)."
"c0789cc30e0766ccdea9e216da799f9cb41f853d","hrv-human","38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .....38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.....the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).....in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).....analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below)."
"1e9929bbb08fb46de40a699d0c2d2aa7c287e5b4","hrv-human","the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .....38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.....the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).....in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).....analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below)."
"99560951f295587952ccb543ccc8c214e6df62ae","hrv-human","in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .....38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.....the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).....in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).....analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below)."
"8d095d0275e474dbb9d9b63a75591ff2c0667d73","hrv-human","analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below).","when sequencing the vp4/vp2 region of the hrv genome, several recent studies have identified new strains of viruses from children and adults with ari, asthma, or otitis, which are clustered differently from hrv-a and hrv-b, and have been classified into a novel hrv-c species [7, 8, 17, 18, 19, 20, 21, 25, 26, 27, 28] .....38 in a recent study by us that aimed to better define the role of hrv-c in adult respiratory illness, eight (62%) of the 13 adults with hrv-c infections had pneumonia, a rate significantly higher than that observed with hrv-a infections in the study population.....the distribution of hrv species differed by age group, with hrv-a (52%) being the most prevalent among infants ͻ12 months of age, followed by hrv-c (38%) and then hrv-b (10%), whereas hrv-c (60%) was more prevalent among children 13 to 59 months of age, followed by hrv-a (38%) and hrv-b (2%, p ϭ 0.002).....in contrast, rsv and the group of other respiratory viruses did not significantly influence the likelihood of hrv-c detection; study subjects showed a 5.8% hrv-c mono-infection frequency compared to 4.6% and 8.6% in those co-infected with rsv and other respiratory viruses respectively (p.0.05).....analyses of different clones for each sample allowed the identification of multiple infections: sample n16 was shown to contain one hrv-a and one hrv-b (n16a and n16b, respectively), while n58 contained one hrv-a and one hrv-c (n58a and n58c, respectively) (see below)."
"943f2beb4d32bce84617c72677a277224b73fd8f","sar-patient","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .....sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).....having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).....eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.....hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients."
"596e1ce4967dd7cbb1fbe4c6b52c3910fee48987","sar-patient","sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .....sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).....having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).....eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.....hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients."
"25b2102f32004f50167c6d6894d5f4fc6a70b99f","sar-patient","having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .....sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).....having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).....eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.....hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients."
"3c1893f7c0ec143b4f173980381354e5cfe6416f","sar-patient","eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .....sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).....having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).....eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.....hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients."
"704f0c7ab057483ee618adfe0926eacab4227187","sar-patient","hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients.","the finding of no infection with sars-cov among hospital b workers in the presence of 33 confirmed sars case-patients may support the hypothesis that, in the absence of a superspreading patient or event, most sars patients will not transmit the virus (3) (4) (5) (6) .....sars patients included probable and suspected sars patients and persons isolated while their cases were under investigation for sars according to the participants' report, rather than by using case definitions (http://www.phac-aspc.gc.ca/sarssras/sarscasedef_e.html).....having three or more personal protection equipment inconsistently used (including masks) was also a significant predictor of sars infection for hospital workers in direct contact with sars patients (or = 7.84, p = 0.003); for those with direct contact with patients in general (or = 10.83, p = 0.0007); and for those with no patient contact (or = 3.4, p = 0.006) (table1).....eleven patients were excluded from the primary analysis: seven had probable sars, one patient was unclassifiable and three patients had at least one specimen positive by pcr, but did not have detectable antibodies to sars cov at $28 days after symptom onset.....hospitals in taiwan were able to care for all sars patients in individual negative-pressure rooms; cohorting of patients in group wards was not necessary, and hospital staffing levels were not strained, as they have been in some cities with far more sars patients."
"9764af198bccd196d117b460ad8112059b4f6b00","cat-felin","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.....moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.....while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.....as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.....another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats."
"f1570e2dfd60e3bc423fede19c89171ac06da885","cat-felin","moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.....moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.....while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.....as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.....another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats."
"9764af198bccd196d117b460ad8112059b4f6b00","cat-felin","while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.....moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.....while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.....as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.....another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats."
"9764af198bccd196d117b460ad8112059b4f6b00","cat-felin","as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.....moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.....while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.....as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.....another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats."
"7387ab0ad7fdb62b372043fc912931583e5c7af0","cat-felin","another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats.","cats aged from one to six years were significantly more frequently felv-positive than younger or older cats (p f < 0.0001; see also table 3 ). 35 were norwegian forest cats, and 30 were birman cats; from the remaining breeds, fewer than 30 cats had been included.....moreover, more cats in group a were p27 antigen-positive compared with those in group b, two cats in group a but none in group b developed persistent infection, and some cats in group b but none in group a became viral rna-negative within the observation period.....while it was shown previously that young cats are more at risk of developing progressive felv infection [24, 91] , the risk of being felv infected in the present study was approximately twice as high in cats aged one to six years compared to younger and older cats.....as for other feline viral infections [34, 92, 93] , and in accordance with results from feline retrovirus studies investigating cats in overcrowded conditions  , keeping cats in groups of ≥5 cats/group was also a risk factor for felv infection in the present study.....another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether il-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats."
"975349ac1c79fc64525ee17e7d088c88c2c2071b","model-diseas","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.....a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .....when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.....in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.....5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact."
"06ebe6e32a2e7241e23d3fb51c4dffeed389861d","model-diseas","a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.....a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .....when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.....in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.....5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact."
"8eef6fec694446e150e95dfbef3a3579ae8806d3","model-diseas","when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.....a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .....when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.....in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.....5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact."
"0b7de7591cf59d3b9e8f9db423431c0850eb0276","model-diseas","in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.....a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .....when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.....in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.....5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact."
"44f01ea111fa2b4bd8ce34739f64b17930bb0ea8","model-diseas","5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact.","a wide range of disease models can be described using the model [15, 10, 36, 1, 44, 37] : where t is time, i(t) is the incidence of new infections, s(t) is the proportion of the population susceptible, and k(s) is the intrinsic infectiousness of individuals who have been infected for a length of time s.....a model which tracks the number of individuals (or proportion of a population) carrying or infected with a pathogen over time, where the risk of transmission to susceptible at a given point in time is dependent on the number of infected (or colonised) individuals in the community  .....when the transmission of an infection is associated with hand cleanliness of the infected individuals (as described by the sir wd model), the probability of a susceptible to get the infection is where i d,i and i w,i are the numbers of 'dirty' and 'washed' infected individuals respectively at airport i and n i is the total population at airport i.....in the homogeneous mixing case, with probability 1/3 an infectious individual infects on average 2 other individuals at time 0 (relative to his/her time of infection), while with probability 2/3 he/she infects on average 1 other individual at time 1.....5 the probability that an infectious individual would infect a susceptible individual was calculated using the following transmission function, which takes into account the disease infectivity of the infectious individual ii and the susceptibility of susceptible individual is , at the time of contact."
"3b8b2a835cfa770c6cef711d52e1f1e869d8aca8","cell-activ","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.....as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).....cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.....the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).....1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment."
"76de3c0c853bd138ae36cf9128ee2fb0943764fc","cell-activ","as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.....as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).....cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.....the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).....1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment."
"80786183397e485664fd049d086f6e3e38ba210f","cell-activ","cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.....as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).....cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.....the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).....1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment."
"26bdc177821e0161d138236656dafefe2f9f6900","cell-activ","the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.....as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).....cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.....the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).....1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment."
"94827ed2231500b8b66fde9844d2aebe81a4aba9","cell-activ","1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment.","coculture of raw 264.7 and 4t1 cells 4t1 cells (5 â 10 4 cells/ml) were plated in 12-well plates, and the 24-hour ttfs-treated raw 264.7 cells were added to the wells for coculture at different densities: 5 â 10 4 cells/ml, 25 â 10 4 cells/ml, or 50 â 10 4 cells/ml.....as shown in table 4 , the parent compound emodin exhibited stronger cytotoxic activity against l02 cells with an ic 50 value of 22.52 ± 0.18 µm than against cancer cell lines (ic 50 = 43.87 ± 1.28 µm against hepg2 cells and ic 50 = 52.72 ± 2.22 µm against mcf-7 cells).....cell viability can be defined as the number of healthy cells in a sample, without any distinction between cells which are actively dividing or quiescent ones, whereas cell proliferation is the measurement of the méry et al 3 number of cells that are dividing in a culture.....the binding of virions to rie-1 cells and 6b72 cells and initial accumulation of virus particles within cells was similar, however fluorescence was almost nondetectable in rie-1 cells ( figure 8a) whereas it was still present in 6b72 cells at 2 hrs ( figure 8b ).....1 niclosamide suppresses cell growth and induces cell apoptosis in hepatoma cells. a qgy7701 and hepg2 cells were treated with indicated concentrations of niclosamide and cell viability was analyzed using cck-8 assay after 72 h of niclosamide treatment."
"8806dfedc1367125f90ab8479b99ae5a50438c1a","viru-cell","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .....however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.....although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .....we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).....these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point."
"bc7b16d381d2acf67eb97db19f1686c90d72ecf1","viru-cell","however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .....however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.....although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .....we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).....these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point."
"6652151e876145926c6b4c6d683346811588bdfa","viru-cell","although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .....however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.....although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .....we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).....these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point."
"4501afb17c42f81f10cefa7c72ef331c15f61fb9","viru-cell","we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .....however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.....although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .....we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).....these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point."
"4501afb17c42f81f10cefa7c72ef331c15f61fb9","viru-cell","these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point.","the same cells persistently infected with aal dnv and reinfected with denv-2 showed an important reduction in the severity and mortality of the denv-2 infection compared with those of noninfected cells, and denv-2 titres were lower than in naïve cells  .....however, infection with denv 2 in the presence of resveratrol (at 25 and 50 μm) in hek293t/17 cells showed a significant reduction in the level of infection (fig. 3c) , while a slight increase in infection levels was seen in hepg2 cells (fig. 3d) with the lowest moi and 50 μm resveratrol.....although there was no significant direct virucidal activity against denv-2 by quercetin, continuous treatment of cells from 5 h before virus infection up to 4 days post-infection exhibited anti-dengue activity with ic 50 = 28.9 μg ml -1 (figure 3a) .....we also confirmed the cleavage and degradation of sting by the denv ns2b3 protease in human mddcs in the context of denv infection, since it is important to validate these findings in a relevant primary cell system and during virus infection ( figure 1h ).....these data suggest that there is a coordinated and distinct kinetic of infection of denv-2 in different cell populations in blood and there is a lack of type i ifn production in those cells after infection with this virus, at least at this early time point."
"7846c73c25fafce260659a9f9aefbef6b514bf15","structur-protein","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .....nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.....matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.....while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .....based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     ."
"ad0a78a68ab4c3beade7409be318f0d13046b922","structur-protein","nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .....nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.....matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.....while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .....based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     ."
"3741c1d2fb8893ca57a949704a64a7a570802543","structur-protein","matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .....nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.....matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.....while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .....based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     ."
"0acc1f9a1c333a9a6b2dbba4a252d7576f024783","structur-protein","while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .....nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.....matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.....while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .....based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     ."
"96c886c9234855e0fb6ef46ea3c5b7c1c7abc652","structur-protein","based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     .","currently there is no high-resolution structure of the ezrin/actin interaction however work characterizing the interaction has revealed that residues thr576, lys577, arg579 and ile580 are intimately involved, with these residues forming a patch on the surface of the last helix of the ezrin structure  .....nevertheless, the structure indicates that 6tg has polar interactions with residues leu269, gln283 and tyr558 and van der waals contacts with nearby residues asn279 and phe573, while may also show a possible covalent bonding interaction between the sulfur atom of 6tg and the thiol group of residue cys276 (fig.....matrix protein interacts with rna in thr123, phe125 and arg134 residues; these are the most important residues close to the interface of the n-and c-terminal domains in the monomeric conformation; which might implicate them in the transition process.....while most correspond to interactions between folded domains, the database contains entries in which structuring occurs upon binding, such as protein-peptide interactions and, in the extreme case, the actr/ncbd interaction in which both binding partners become ordered upon binding  .....based on those previous works, the proposed mechanism for binding involves two interactions: between the n-loop of cxcl-8 and the n-terminal domain residues of the receptor cxcr1 (site i) and between the n-terminus of cxcl-8 and the ec loops residues of cxcr1 (site ii) [15,     ."
"d37ad55db18a412c55ca07e3780ab65ec8040908","base-sequenc","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.....for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).....the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.....the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).....up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] ."
"be45cd588caaa0d8e5cdcd0cb7a1a59ccfc85d51","base-sequenc","for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.....for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).....the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.....the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).....up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] ."
"5e01fabcf9b38073be541d0ac1c9f147c99a7af7","base-sequenc","the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.....for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).....the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.....the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).....up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] ."
"ba3471e86d6880f42f1df67c9a381e83216d1b45","base-sequenc","the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.....for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).....the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.....the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).....up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] ."
"18d1ff1667652b4e383a0a1ea258db97ac74735c","base-sequenc","up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] .","thus far, a variety of protein disorder prediction methods have been developed and have been widely used, not only in traditional bioinformatics domains, including protein structure prediction, protein structure determination and function annotation, but also in many other biomedical fields.....for the study of both accuracy and performance, we plug seven rna secondary structure prediction programs into our framework for both the chunk-based predictions and the predictions of the same sequences without chunking (the whole sequence is taken).....the method of pancaldi and bähler  , which was developed to predict mrna-protein interactions (rather than ncrna-protein interactions), also uses rf and svm classifiers, but requires a much more extensive set of features regarding the mrnas and proteins.....the function sequence identity(p, p m ) returns the sequence identity between the protein sequence p and another protein sequence p m having mechanism m (the emitted value can span from zero, if no amino acids could be aligned, to one, if the two sequences are identical).....up to now, all the computational algorithms have only used single machine learning methods for the analysis and prediction of protein-protein interactions      , or the statistical analysis of interacting patches of protein surfaces [75, 149, 161, 162] ."
"7e951ff88008de16ecc2aeaecea54ed5b5c84abf","travel-diseas","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).....we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.....of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.....although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.....while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications."
"b936109e0b0de2cb59b2ed271614bb710e8e04af","travel-diseas","we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).....we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.....of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.....although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.....while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications."
"08660499ee722a74043f8417faee3e1eeb9d0f5f","travel-diseas","of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).....we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.....of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.....although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.....while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications."
"7e951ff88008de16ecc2aeaecea54ed5b5c84abf","travel-diseas","although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).....we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.....of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.....although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.....while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications."
"11f96d05db6854ef95312aa3a4736724ce1f02d6","travel-diseas","while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications.","the seasonal influenza vaccination coverage for the preceding 5 years was 20ae8% (20 ⁄ 96), being statistically significantly higher for older (>60 years old) travellers (66ae7%; 4 ⁄ 6; p-value = 0ae018) than younger travellers (18ae6%; 16 ⁄ 86), and for travellers with an underlying medical condition (45ae5%; 10 ⁄ 22; p-value = 0ae026) when compared against healthy travellers (13ae5%; 10 ⁄ 74).....we acknowledge that the number of infected travellers was relatively small at 30 but the probability is only 0.005 (0.5%) that the prevalence of fever among the population of infected travellers arriving from australia into christchurch at this time was greater than 18%; in other words the vast majority of infected travellers in this population were afebrile.....of the travel-associated zika cases diagnosed in florida (n = 1,333), 49% were visiting friends and relatives, 17% were refugees or immigrants, 17% were traveling for tourism, 3% were traveling for business, and 14% were traveling for unknown or other reasons.....although our findings suggest that there is a role for travel clinics in both the prevention and treatment of influenza in travellers, corroboration of our findings in other travel clinic settings and among different cohorts of travellers is desirable.....while a travel ban for entry with history of travel to all high-risk regions would indeed likely further limit the number of infected travellers entering to those who enter by different means, it would also come with substantial economical implications."
"f291cfbcb64f14deb49a2dcc95079a17e838cf85","respiratori-viru","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).....however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .....twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .....in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .....previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children."
"372c5fab99bbe7f7862304f94bfaebd3c02f1e1c","respiratori-viru","however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).....however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .....twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .....in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .....previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children."
"2a90543a82ae4b2916e12f6294b7a37aa8142942","respiratori-viru","twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).....however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .....twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .....in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .....previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children."
"4c0a84d9d35e76db288afca33c1f63c27d436328","respiratori-viru","in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).....however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .....twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .....in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .....previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children."
"c4ad1eb3352c4b02e769ba152f1fa89209a0e70a","respiratori-viru","previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children.","the prevalence of respiratory virus detections was higher among young children (<5 years) than older children and adults (≥5 years) the most common respiratory viruses detected in this study were rhinovirus 18.6% (n=1050), influenza virus 6.9% (n=390), coronavirus 6.8% (n=387), parainfluenza virus 6.6% (n=371), rsv 3.9% (n=219) and adenovirus 2.7% (n=155).....however, the study for respiratory viral infection of previously healthy children in similar area revealed different results that rsv (23.7%) was the most common detected virus, and as followed adenovirus (6.8%), piv-3 (6.2%), rhinovirus (5.8%), and hmpv (4.7%) (17) .....twelve years' detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay respiratory infections are a major cause of morbidity and hospitalizations in children  , of which a significant proportion are caused by viruses [2, 3] .....in a prospective study of community-acquired respiratory viral infections in ltrs, rsv infection occurred in eight (23%) of 35 ltrs and was associated with a high rate of ar (88%) in comparison to other respiratory viruses [hmpv, n = 4 (25%); piv, n = 11 (55%); influenza a/b, n = 9 (56%); rhinovirus, n = 2 (0)] (32) .....previous studies have reported significant association between younger age and coinfection in adv infection, as is the case with other respiratory viral infections [18, 19, 21, 22] , and the present study also showed a significant increase in coinfection frequency in children younger than 24 months of age than that in older children."
"1f63075aa219ae29132b49a0c7277632b9b31ba8","patient-respiratori","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.....the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.....thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.....our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.....conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald."
"d03888523e81c821f95247b544bdfac0c94a8b0c","patient-respiratori","the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.....the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.....thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.....our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.....conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald."
"b3deae058a2e470aac4ba8f9425c6150575f1522","patient-respiratori","thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.....the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.....thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.....our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.....conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald."
"250c1f24a22bcb81973ea532f8236838987e0872","patient-respiratori","our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.....the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.....thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.....our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.....conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald."
"2e2bc679c8393230bac2af64115bab7ed1ba62c0","patient-respiratori","conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald.","the or for si ≥1 in patients ≥65 years was 8.2 (ci 7.2 to 9.4) compared with 18.9 (ci 15.6 to 23.0) in younger patients. β-/ca 2+ channel-blocked patients had an or of 6.4 (ci 4.9 to 8.3) versus 12.3 (ci 11.0 to 13.8) in nonusers, and the or for hypertensive patients was 8.0 (ci 6.6 to 9.4) versus 12.9 (ci 11.1 to 14.9) in nonhypertensive patients.....the following underlying conditions were present: chronic obstructive pulmonary disease in 67 patients, neuromuscular disorders in nine patients, acute lung injury as a result of surgery in 14 patients, asthma in six patients and miscellaneous causes in eight patients.....thus, a total of 123 patients were included after presenting with febrile neutropenia and study samples for virus analysis were collected upon admission (27 patients) or within 24 hours (48 patients), within 48 hours (31 patients), and within 72 hours (17 patients) from admission.....our patients are in different stages of therapy: 37 patients at the end of follow-up (ef) -42.52 %, 30 patients at the end of therapy (eot) -34.48 %, 5 patients during the third month of therapy -5.74 %, 10 patients during the second month of therapy -11.49 % and 5 patients during the first month.....conclusions these results suggest signifi cant increased icu mortality in the following groups: over 50 years old, smokers, patients with poor exercise tolerance, patients with ihd or pv, patients with copd and patients who drink alcohol to excess or those with ald."
"85f3c300e460e62364ef4a74fb1289334a5c2317","ibv-viru","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.....ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.....the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.....in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .....the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains."
"bd57ac5cebeff6091e3ca6756a1efcf1c692b0f3","ibv-viru","ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.....ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.....the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.....in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .....the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains."
"1c8afcb822dac8e8e5b33a85c2c2e9c7cc24a25a","ibv-viru","the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.....ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.....the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.....in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .....the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains."
"60cc55d9df1b0ff215bcaefe413b7b6edc5eb182","ibv-viru","in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.....ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.....the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.....in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .....the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains."
"1c8afcb822dac8e8e5b33a85c2c2e9c7cc24a25a","ibv-viru","the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains.","fowlpox viruses that express the ibv s1 gene have been reported previously    , and all of these vaccines have been described to confer protection against viral challenge with homotypic ibv strains and some heterotypic ibv strains in spf chickens.....ibv strains in australia can be classified into three groups based on the s1 gene: australian group 1, containing vaccine and vaccine-like strains, group 2, emerging from the 1980s to the 1990s, and group 3, containing newly isolated recombinant strains from groups 1 and 2.....the accession numbers for other ibv gene sequences used in this study are as follows: (a) complete structural genomes:  in this study we analyzed ~7.2 kb of the 3' genomic end of the ibv strain md27 and compared it with other ibv strains and coronaviruses from different parts of the world.....in brazil, since the last decade, despite the frequent use of massachusetts ibv vaccines, a high number of variant ibv isolates have emerged; these strains have been phylogenetically classified by s1 gene sequencing under a separate genotype of brazilian strains (br-i genotype) [5, 12, 13, 16, 19, 24, 36] .....the md27 strain has never been characterized by sequencing and it is essential to sequence these typical strains to understand the evolution of ibv geographically and also to implement an effective vaccination program to control new variant ibv strains."
"32501343a772539b8477e17940f7333e8678fe5f","perform-effect","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).....as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).....application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .....in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.....however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests."
"3a83391556631ba5fbdbef16900ceed1619d69f3","perform-effect","as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).....as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).....application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .....in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.....however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests."
"9d02db669e8701c83186d7d3aae69da2f2cb3d34","perform-effect","application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).....as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).....application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .....in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.....however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests."
"92e99304d6df52227598a5da5996127ee119f6fa","perform-effect","in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).....as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).....application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .....in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.....however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests."
"dc352893117f666477e7cf7c8c614bdf60592178","perform-effect","however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests.","in the 20 kg pigs (pigs number 5-11), the number of blood samples was reduced to 26 samples per tracer: every 5 seconds for 50 seconds (10 samples), at 60, 80, 100, 120, 150, 180, 240, and 300 seconds (8 samples), and at 6, 8, 10, 15, 20, 30, 40 , and 55 minutes (8 samples).....as shown by the mean cfu numbers ± standard deviation (sd) presented in fig 4a-4c , no sample was completely inactivated, although cfu numbers in samples treated with detergents for 24 h were significantly lower than in the control samples (p < 0.001).....application of pvp-i products with concentrations of 0.23-1% for 1-2 min reduced sars-cov virus infectivity from 1.17 9 10 6 tcid 50 /ml to below detectable levels in a study by kariwa et al., although shorter contact times were not investigated  .....in this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the blg extraction procedure (batch no.....however, the effects of sampling time on the fungal bioaerosol recovery were found not statistically significant both for regular agar(p-values = 0.87) and mineral oil (p-value = 0.879) plates with the biostage impactor by independent sample t-tests."
"6ae480b7554d3210fa26f2410a6ed06ade025eec","ferret-viru","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.....due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.....despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.....when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).....to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets."
"4b382dd30271d1544237000616b02988687c4402","ferret-viru","due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.....due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.....despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.....when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).....to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets."
"60f1a9fff7e34e6a528a2a06dedb23700c87e114","ferret-viru","despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.....due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.....despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.....when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).....to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets."
"1ce2ec3b5d92a3f2ace27a00bde0165ba6761aa0","ferret-viru","when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.....due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.....despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.....when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).....to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets."
"8ace20b674c2bc5f71e195f68c703f66efd97b8b","ferret-viru","to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets.","to compare the distribution of h5n1 virus in animals infected via the conventional method with that in animals infected via the aerosol method, animals from each group were euthanized on day 4 post-infection and organ samples were collected for virus titration.....due to the respiratory-infecting characteristics of ev-d68 in humans, the infection efficiency of the virus in ferrets could be a key animal model for conducting studies of the ev-d68 infection mechanisms and immune responses via the respiratory tract.....despite these challenges, increased sneezing is routinely reported in ferrets infected by influenza viruses [26, 38, 39] so the contribution of virus-laden aerosols expelled by ferrets during sneezing to transmission cannot be ruled out for this animal model.....when ferrets were first infected with a(h1n1)pdm09 virus, for every day that a(h1n1)pdm09 virus was detected following challenge, the start of b virus shedding was delayed by 1.82 days (95% ci, .31-3.33; p = .031; figure 5a ), and the peak of b virus shedding was delayed by 1.68 days (95% ci, .66-2.69; p = .014; figure 6a ).....to characterize the viral shedding profile of infected animals and to study potential animal-toanimal transmission, groups of 4 ferrets were infected in with 5,000 tcid 50 of hev, niv-b and niv-m, and each of these groups was co-housed with 4 naïve ferrets."
"6885e0e09ec18e5a9ec6e40efb3645824f25fe79","ebola-outbreak","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .....4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.....because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  ."
"57eb12d93057a4bc1a043420327251b2327c9b39","ebola-outbreak","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .....4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.....because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  ."
"63e680dd648bb477a87f55d53d3f0ff3f2c18e0a","ebola-outbreak","r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .....4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.....because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  ."
"61c74b574c1b33ece0ca2f53861597d70c61a720","ebola-outbreak","4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .....4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.....because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  ."
"873d2ca5817ad916b491680ffc9e3260a8469e60","ebola-outbreak","because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  .","        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....        as there is a difference in the ebola response system as well as community sensitization to evd following a country's first outbreak, we employed this inclusion criterion to reflect the ebola response system in drc during what is now its ninth outbreak.....r 0 has been estimated for prior evd outbreaks in central africa using mathematical modeling and epidemiological data for two ebola outbreaks, namely the 1995 outbreak in democratic republic of congo and the 2000 uganda outbreak, respectively [30, 31] .....4 experiences of evd preparedness and response in hospitals outside the ebola epidemic area have been described before      ; however, the cooperation between the curative and public health sectors in a high-income country has not been addressed.....because the purpose of our estimate is to illustrate what could have happened had the ebola outbreak of west africa expanded beyond the three mostly affected countries, we used the best estimate from who for the west africa outbreak, i.e., an infectious period of 8 days  ."
"8987e37e0598cf67e121bc72d1b95b8f1d9fde73","genom-sequenc","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).....dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).....therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .....with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.....let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively."
"8987e37e0598cf67e121bc72d1b95b8f1d9fde73","genom-sequenc","dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).....dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).....therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .....with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.....let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively."
"93dae518889d2a93960963fa3e99158f58738eda","genom-sequenc","therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).....dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).....therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .....with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.....let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively."
"6658283efba628db14a76984b7d3f39d79712f4c","genom-sequenc","with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).....dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).....therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .....with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.....let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively."
"d0c4236f95ba2b3d5cdc71fde524b26262f05dd3","genom-sequenc","let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively.","dataset 1 comprised 29 nucleotide sequences from the p1 structural region (2291 nt) from different hpev isolates (12 sequences of hpev1, 1 sequence of hpev2, 4 sequences of hpev3, 5 sequences of hpev4, 2 sequences of hpev5, 3 sequences of hpev6, 1 sequence for hpev7 and 1 sequence for hpev8).....dataset 2 comprised 199 nucleotide sequences of the vp1 capsid region (647 nt) (117 sequences of hpev1, 2 sequences of hpev2, 40 sequences of hpev3, 18 sequence of hpev4, 9 sequence of hpev5, 10 sequences of hpev6, 1 sequence of hpev7, 1 sequence of hpev8 and 1 sequence of hpev14).....therefore, we want to find a sequence of numbers, each of which uses the global information of the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n in  a novel construction of genome space with biological geometry [vol. 17, such a way that this new sequence of numbers determines and is determined by the sequence of numbers 1 2 y 1 , 2 2 y 2 , . . . , n 2 y n .....with the advent of advanced sequencing technologies, such as single cell genome sequencing [56, 57] and the third generation sequencing technology which is able to sequence longer reads  , we can reveal the mechanism of virus integration more deeply.....let n be a point within a dna sequence of length n ) 1 2 ( n n , which divides the whole sequence into two parts: the right and left sub-sequences, and then denote frequencies of bases in the right sub-sequence and left subsequence by (a r , c r , g r , t r ) and (a l , c 1 , g 1 , t 1 ), respectively."
"e67d66fb0773322520aa527d533c6cffb08016a2","viru-sampl","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .....we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .....in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .....using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .....in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 ."
"ea36a40b76e233b4f7d69d38d9ce3741ccd710b4","viru-sampl","we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .....we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .....in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .....using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .....in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 ."
"55248fb2e12f9712b35a26e3fdb723baea0ac775","viru-sampl","in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .....we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .....in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .....using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .....in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 ."
"a286c95345592981acce2ffe297605fd083d9fe7","viru-sampl","using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .....we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .....in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .....using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .....in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 ."
"7360f5cfdd468aea794a9eb68291950862c8fcb0","viru-sampl","in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 .","the aetiology of the disease was confirmed to be a virulent strain of pedv (it was thereafter designated the jimei strain); the sequence of this strain is almost identical to that of the strain that caused the epidemic outbreak of pedv in the us in 2014  .....we determined that the full-length spike genes of the pedv strains were 9 nt longer than that of the prototype pedv strain, cv777; this difference was caused by the presence of genetic signatures for recent pedv field isolates as described elsewhere (10) .....in the analysis of the genomes of the pedv strains detected in the usa, most were grouped in the high mortality type similar to the chinese pedv strain (ah2012), and the remaining strains were grouped in the indel type, which have specific insertions and deletions in the s gene [9, 10] .....using this approach, we were able to show that the selected chinese pedv field strains between 2011 and 2015 show a significant increase in diversity when compared to early chinese pedv strains, which is in line with previous reports about pedv variants  .....in this study, we found a pedv strain jsc1601 with new genetic characteristics while elucidating the molecular characteristics and phylogeny of pedv field previous studies have demonstrated that the 5′ utr of pedv strains were highly conserved 7,13,32 ."
"1174cadd31854c1128f0bbf2a61d31b2b72f61c3","diseas-test","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .....studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .....roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).....in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .....by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity."
"1174cadd31854c1128f0bbf2a61d31b2b72f61c3","diseas-test","studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .....studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .....roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).....in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .....by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity."
"4cd8e92fcab8da2c840ff39f14ca35bf5ba6e444","diseas-test","roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .....studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .....roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).....in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .....by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity."
"e6d560c0ed2c420b3ca34de569c8a46d3722e2da","diseas-test","in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .....studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .....roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).....in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .....by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity."
"4cd8e92fcab8da2c840ff39f14ca35bf5ba6e444","diseas-test","by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity.","the most commonly reported outcomes were duration of hospital stay (n = 6 studies) [17, 19, 21, 28, 29, 31] , time to symptom resolution (n = 6 studies) [18-20, 29, 31, 33] , cure rate (n = 3 studies)    , and clinical severity scores during hospitalization (n = 4 studies) [17, 21, 28, 30] .....studies of chinese herbal medicine (4 studies, n = 365), vitamin d (1 study, n = 89), n-acetylcysteine (1 study, n = 100), and magnesium (2 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 bronchiolitis is the most common acute lower respiratory tract infection of viral origin among infants  .....roc plots can be used to present the results of diagnostic systematic reviews, but differ from those used in primary studies as each point typically represents a separate study or data set within a study (individual studies may contribute more than one point).....in this study, cronbach's alpha estimated for the a-ecohis as a whole was similar to that estimated in brazilian and lithuanian studies (0.86) [27, 29] , and slightly higher than those of the french (0.82)  and malay studies (0.83)  , but lower than those of other studies (0.91 to 0.99) [24, 25, 31] .....by using different symbols to illustrate studies that did (diagnostic cohort studies) and did not (other study designs) include an appropriate patient spectrum we were able to show that studies that included an inappropriate patient spectrum grossly overestimated both sensitivity and specificity."
"10a769cac0a76b41a6a82be148c1a2675e9d4604","cell-viru","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .....however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.....in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.....among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .....we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines."
"7d0c3cb7b6d6dfcb416028248132542c99f80ba0","cell-viru","however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .....however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.....in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.....among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .....we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines."
"4b3ddd160ebda77b58843d167709d71a73a3bf4a","cell-viru","in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .....however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.....in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.....among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .....we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines."
"8a45b8b7e677272ce3d5d750e943fe6584134a97","cell-viru","among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .....however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.....in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.....among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .....we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines."
"040c9714be80e4a337f6737d17e94171c25cc076","cell-viru","we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines.","when htim1-293t cells and the control hace2-293t cells were infected with serially diluted viruses, infection levels were markedly enhanced in htim1-293t cells across the board, except for h1n1 (fig. 2) , which is consistent with the pseudovirus entry data shown in figure 1 .....however, although these proteins may play a role in attachment or entry of certain cell types, the ability of marv to infect cells lacking these receptors [92, 93, 168] indicates that there might be redundancy in cellular molecules required for marv attachment to cells.....in hpiv-2 infected cells, np, f and hn proteins were observed in almost all the cells: np protein was observed in many strong fluorescent dots mainly in the cytoplasm, while f and hn proteins were in small dots in the cytoplasm and on the cell surface.....among the target cells supporting viral replication are monocytes, macrophages, dendritic cells (dcs), hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells                .....we could show that the neuroblastoma sh-sy5y cell line is specifically resistant to filovirus infection although all intracellular proteins known to be essential were expressed, and although its overall transcriptome was very similar to that of susceptible cell lines."
"15228615c1656f39a5ec8dcc8bc26ef0371d4040","influenza-viru","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.....this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .....a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.....as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.....the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      ."
"680c8cd646f4f78d97eddff21292668beba44d09","influenza-viru","this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.....this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .....a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.....as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.....the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      ."
"15228615c1656f39a5ec8dcc8bc26ef0371d4040","influenza-viru","a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.....this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .....a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.....as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.....the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      ."
"4518da3d4fdddd13a397a1fd68ce915512615db2","influenza-viru","as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.....this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .....a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.....as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.....the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      ."
"2fa46e22a7460345c3a4aed5aca12df56667cb56","influenza-viru","the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      .","thus, we examined whether influenza viruses can infect the cell which had already been infected, using ts53 mutant and wild-type influenza virus a/wsn/33. ts53 virus has a substitution mutation from u to c at the nucleotide position of 701 in the pa gene.....this is the first study on the effect of iav on ati-like cells and the results are in agreement with studies showing involvement of caspases in apoptosis upon influenza virus infection in cell lines and human monocyte-derived macrophages [43, 48, 49] .....a polyclonal antibody with the neutralizing activity against influenza virus particles inhibited infection of cell-free viruses to less than 50% at the concentration of 0.03%, although the cell cluster formation was observed at the concentration less than 0.01%.....as shown in fig 7, the abundance of np protein at early time points (0.5 and 1.5 h p.i.) was lower in p518-l infected 293t cells than in p518-s infected 293t cells; importantly, comparable np protein levels were detected in cells infected by these two strains at 6 h p.i.....the main cell targets for influenza viruses are epithelial cells in the lungs, which express tlr3 and rig-i [25, 26] , both of them important for the induction of type i ifn upon sensing of influenza virus replicative and genomic rna      ."
"4ee51bb838b0cdc2e59317a4b837f2997795b665","influenza-season","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.....with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .....influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.....influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .....any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b."
"27c85eb0542256f6599ba43e90986abfdb1ddc5b","influenza-season","with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.....with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .....influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.....influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .....any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b."
"80c9179236f8b034ec0763a86209141ea894b2ec","influenza-season","influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.....with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .....influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.....influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .....any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b."
"b2e781c81e340e91a0f27009b29d0c8a3635c5e8","influenza-season","influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.....with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .....influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.....influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .....any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b."
"80eae3b5b1d0ba7f1806d637628b15ae10e342c4","influenza-season","any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b.","during the 2009/10 influenza season, the laboratory network just carry out the laboratory diagnosis of influenza a(h1n1)pdm09 infection requested by the national health service and the samples were only tested for the influenza a (h1n1)pdm09, influenza a(h1), influenza a(h3) and influenza b virus.....with regard to influenza subtypes, we note that most seasons in the united states were dominated by influenza a (h3n2) virus (30) ; the greatest number of influenzaassociated deaths were associated with influenza a (h3n2), followed by rsv, influenza b, and influenza a (h1n1) virus (31) .....influenza a(h1n1)pdm09, influenza a(h3n2) and influenza b viruses co-circulated in all  while useful information has been obtained from influenza surveillance in west africa, this analysis demonstrates some key weaknesses in influenza surveillance during this time period.....influenza surveillance data between 2012 and 2014 in ghana indicated 1041 positive influenza cases out of a total 8601 respiratory samples tested, with 6 different subtypes [influenza a (h3, h1n1, h1, h5) and influenza b (victoria, yamagata)] identified  .....any specimen positive for more than one influenza result was assigned a single result for analysis according to which type ranked first according to the following hierarchy (based on perceived public health importance): influenza a/h1n1pdm09, influenza a/h3n2, influenza a/h1n1, and influenza b."
"6d76fbc0763d467e9109feefe43e4e52113b78f3","posit-sampl","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .....of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.....dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.....to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.....in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) ."
"2f00227d35cee08706713c7085ec576b74ff2f9a","posit-sampl","of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .....of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.....dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.....to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.....in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) ."
"2f00227d35cee08706713c7085ec576b74ff2f9a","posit-sampl","dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .....of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.....dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.....to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.....in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) ."
"a4ee11dba58a0b0c6566a1fac060b4329bcdc8cd","posit-sampl","to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .....of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.....dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.....to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.....in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) ."
"deff02a187178ad474a1c556ff4f134d48300ce9","posit-sampl","in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) .","although no other respiratory virus was identified in this sample, wu polyomavirus presents low prevalence in cases of respiratory infection and high rates of co-infection with other common respiratory viral pathogens, and further studies are needed to ascertain its clinical significance    .....of interest, including the ngs results, 79.2% (198/250) of the samples had a respiratory virus detected, and in the remaining 52 samples at least one bacteria was found, such that all 250 samples from children with lrti had a respiratory pathogen identified.....dna sequence reads from at least one virus commonly associated to respiratory infections was found in 20 out of the 25 double-negative samples of lrti patients (table 4 ): 5 samples were positive for rsv reads, 11 samples for hcov-oc-43, and 9 for rv.....to the extent that we needed a large number of samples characterized by many markers for statistical analysis (age of the sampled patient, detected viral target, etc.), a prospective study on freshly sampled respiratory specimens could not be performed.....in our study, 7 of the patients had respiratory symptoms, and virus shedding in saliva is known to occur for several respiratory viruses, such as severe acute respiratory syndrome-associated coronavirus, respiratory syncytial virus, and human metapneumovirus (22, 23) ."
"7941d4720a1cb228b2380a42885532440f5b7a0a","detect-sequenc","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.....a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.....we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.....sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .....using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  ."
"7aac0f55c8b869e13f1c2678207430bc9203d65e","detect-sequenc","a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.....a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.....we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.....sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .....using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  ."
"fca7adbc5fdaeba0fedd1201e496704b1a888556","detect-sequenc","we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.....a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.....we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.....sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .....using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  ."
"ba394664ad45d9f543519112dcd3dc4b3a213413","detect-sequenc","sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.....a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.....we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.....sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .....using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  ."
"c3c131a47ced4db370181524292fac5627fb6389","detect-sequenc","using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  .","it could be that these sequences are derived from yet unknown viruses, or it could be that the sequences are part of a genomic sequence from a known organism, e.g. a bacterium of which not the complete genomic sequence is present in the genbank databases.....a blastn sequence alignment between the sars-cov genome and the five nonredundant conserved sequences shows that the longest conserved sequence in group 1 had 80% (79/98) sequence similarity with the sars-cov genome at nucleotide positions from 15732 to 15829 ( fig.....we performed sequence alignments between the primers designed based on the refseq sequences and the genome neighbor sequences, and then inserted information regarding which neighbors can be detected using each primer pair into the mrprimerv database.....sequence-independent methods are attractive in that they allow sequencing of highly divergent viruses, but efficient reduction of background nucleic acids is required in order to get good coverage and depth (number of times each nucleotide is sequenced) of the viral genomes  .....using illumina high-throughput sequencing, genome sequences of both a laboratory strain (f) and a low-passage clinical isolate (h129) were obtained and compared with the available genome sequence of a more virulent isolate of hsv-1 (strain 17)  ."
"3b5290a5bd5c9ac633320eed77f1a7929d72b749","hcov-human","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.....the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.....further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).....gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .....hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) ."
"4c9604ca5c3d30db29127225cc52ad90b50c1b13","hcov-human","the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.....the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.....further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).....gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .....hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) ."
"123db7e17bb17a0d4ff1e7ef87cb629d6ac78125","hcov-human","further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.....the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.....further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).....gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .....hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) ."
"79e0f0277142b321ccd75630f2405565e2ee64f3","hcov-human","gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.....the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.....further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).....gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .....hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) ."
"e0494e196f7f6d783c5c05ac339d19934c000c1f","hcov-human","hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) .","recently, dijkman et al. 41 demonstrated that hcov-oc43 and hcov-nl63 may elicit immunity that protects from subsequent hcov-hku1 and hcov-229e infection, respectively, which would explain why hcov-oc43 and hcov-nl63 are the most frequently infecting hcovs.....the same trend can be observed for hcov-oc43 (χ 2 = 112.955, p<0.05) and hcov-229e (χ 2 = 19.255, p<0.05), but it is interesting to see that for hcov-nl63 and hcov-hku1, a higher epidemic peak can be seen in 2012 and 2014 (for hcov-hku1) (fig 4, χ 2 = 24.125 and 22.110 respectively, p<0.05) , when detection rates of hcov-oc43 and hcov-229e were relatively lower.....further human coronaviruses complete genome sequences included hcov-hku1 (kf686341.1), hcov-nl63 (dq445911.1), hcov-229e (jx503061.1), hcov-sars (ay291315), and two hcov-mers (kj156949 from a strain detected in a human patient and kj713299.1 detected in a dromedary camel).....gerna et al. found a high incidence of hcov-229e, hcov-oc43, and hcov-nl63 infections in infants and children with bronchitis, bronchiolitis, or pneumonia, but most of the lrtis were demonstrated in children co-infected with hcovs and other respiratory viruses (37) .....hcov-229e, hcov-oc43, hcov-nl63, and hcov-hku1 are usually associated with relatively mild respiratory symptoms and the detection rate ranges from 0.3 to 4.5% in respiratory specimens according to different studies (gaunt et al., 2010; gadsby et al., 2016; trombetta et al., 2016) ."
"196d55353760e8e1ddbc2e2cce92f806351b747c","chikv-viru","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .....these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.....supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).....the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).....as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 )."
"977007f901c5697f613ad1b475532ebaf7baef86","chikv-viru","these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .....these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.....supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).....the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).....as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 )."
"49fbca70a4e7e3018cab7eb445683c58fd06bce2","chikv-viru","supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .....these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.....supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).....the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).....as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 )."
"196d55353760e8e1ddbc2e2cce92f806351b747c","chikv-viru","the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .....these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.....supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).....the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).....as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 )."
"c9b6f3ff358477fe654fa5e92b3fb85ebd3fb8a5","chikv-viru","as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 ).","it was observed that the percent positive cells for nsp2 were reduced from 8.19 ± 0.35 (chikv+dmso) to 2.50 ± 0.08 (chikv+sb 0.5 µm) and 1.36 ± 0.02 (chikv+sb 1.5 µm), whereas the percent positive cells for p-p38 were reduced from 8.05 ± 0.73 (chikv+dmso) to 1.31 ± 0.15 (chikv+sb 0.5 µm) and 0.46 ± 0.04 (chikv+sb 1.5 µm) (figures 2b,c) .....these experiments were carried out to determine the possible synergistic role of peptides in the enhancement of pathology in chikv infection: all the mice were confirmed to have chikv infection by the detection of anti chikv antibodies in the serum by elisa.....supplementary table 1 presents the localization of arthralgias by infection outcome for patients with confirmed chikv only and dual chikv-zikv infection: arthralgias in chikv-only patients were most common in the knee (48.9%), wrist (44.7%), and ankle (36.2%).....the inhibition of p-jnk by sp at 5.0 µm concentration did not affect nsp2 expression in the macrophages as compared to the dmso control (chikv+dmso; 7.63 ± 0.40, chikv+sp 5 µm; 7.21 ± 0.17, p > 0.05), despite significant reduction in the p-jnk percent positive cells (chikv+dmso; 6.08 ± 0.40, chikv+sp; 3.31 ± 0.75, p < 0.05).....as we previously described during neonatal sinv infection  , the expression of isg15 during chikv infection was also dependent upon intact ifn signaling since ifnar 2/2 pups infected with chikv did not induce detectable levels of isg15 ( figure s2 )."
"e584b536fcbb3da70855c7f8d81c15319b0e9b7b","rsv-viru","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.....our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.....the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.....the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .....some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) ."
"e584b536fcbb3da70855c7f8d81c15319b0e9b7b","rsv-viru","our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.....our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.....the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.....the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .....some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) ."
"ac04992c38f8d8bb758a7460e350827c390698a1","rsv-viru","the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.....our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.....the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.....the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .....some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) ."
"8762daff0f7890b72f611247c1a15133ea291afb","rsv-viru","the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.....our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.....the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.....the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .....some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) ."
"f5de8066a6e6df907e2389816f2372a427235a9f","rsv-viru","some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) .","the proportion of children infected with rsv-a  after its first detection in germany in 2011/12, rsv-a on1 co-circulated with rsv-a non on1 genotypes and had largely replaced rsv-a non-on1 genotypes in 2013/14, thus demonstrating a very rapid and effective spread.....our investigation is one of only few studies describing rsv-a on1 separately for children requiring outpatient primary care  , and indicates similar disease severity for outpatients infected with rsv-a on1 and those with rsv-a non-on1 infections.....the overall impact of rsv alone on receipt of chemotherapy or immunosuppressive therapy was difficult to assess, but in this group of immunocompromised middleaged children who were likely to have previously experienced rsv infection, the immediate consequences of rsv infection were generally not severe.....the situation is more intricate as some authors report that coinfection with non-rsv respiratory viruses tends to increase rsv severity  and also there is a hypothesis of a synergistic association of rsv with other viral or bacterial infections  .....some studies compared the differences of cytokines between rv and rsv and they concluded that the rv infection had markedly higher systemic levels of il-5 and il-13 than rsv infection when there was a close correlation between rv infections and atopic characteristics 5, 28) ."
"b70653608d4d8838aaf1dae4e710fa03a858df43","sequenc-rna","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .....first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).....since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .....after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.....frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro."
"4ec1787f65505b0751777ff1f2cb40d13c0d2b96","sequenc-rna","first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .....first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).....since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .....after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.....frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro."
"8bb9d8f7eeb8272924275f349e5c63a5bb006445","sequenc-rna","since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .....first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).....since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .....after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.....frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro."
"03ea3a614b56409d3f099c9ad764864293132540","sequenc-rna","after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .....first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).....since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .....after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.....frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro."
"308a157fe5e9a630ded41e9d708dd50df3b6149b","sequenc-rna","frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro.","frameshift sites often contain additional rna structural elements 3´of the slippery sequence that further stimulate frameshifting; in most viruses the downstream structure is a pseudoknot, although stem-loops and protein binding sites can also be used     .....first, one has to identify in mrnas the requirements for a productive frameshift peptide: one might argue that a slippery sequence and a pseudoknot are a good predictor of frameshifting events, but-as pointed out above-there are alternative mechanisms that result in frameshifting (see also figure 2 ).....since mutational analysis revealed drastic changes of ribosomal frameshifting efficiency upon disruption of pseudoknot structure, this structure is likely to be kept intact in addition to the slippery site and spacer region for efficient frameshifting  .....after renormalizing the fluorescence, we found frameshifting sites with translation in both the 0 and -1 frames had 7.8 ± 0.7 ribosomes total, 1.9 ± 0.3 of which were frameshifted, while 0-frame only translation sites had 3.2 ± 0.1 ribosomes and -1-frame only translation sites had 3.4 ± 1.4 frameshifted ribosomes (fig.....frameshift assay using either of the reporters indicated that the selected viral rna sequences possess a frameshift efficiency of 60% (data not shown), which suggests that the sars 13 369-13 520 rna contains an efficient à1 frameshifting stimulator in vitro."
"228edf7f7e53e88e246fc77b7b7664ac35d7278e","speci-human","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.....despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .....the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.....interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.....the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 )."
"eec44b63232c7b965ed908e716003135f358ab57","speci-human","despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.....despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .....the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.....interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.....the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 )."
"c64f525d77bf8b2ae4439a875f1bd8eb197a0519","speci-human","the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.....despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .....the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.....interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.....the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 )."
"c64f525d77bf8b2ae4439a875f1bd8eb197a0519","speci-human","interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.....despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .....the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.....interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.....the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 )."
"c64f525d77bf8b2ae4439a875f1bd8eb197a0519","speci-human","the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 ).","the primary focus of this paper was to explore which mammalian host species might be the 193 most important for spreading viruses due to their sharing of viruses with others, and we were 194 interested in the phylogenetic and functional diversity of host species infected by different 195 virus species.....despite being recognised for many years (1, 6) , investigations on the impacts of multiple infections on individual hosts or higher parasite species richness on host populations or species are still scarce in disease ecology and in evolutionary ecology (7, 3) .....the analysis of the homogeneity of prevalence of a virus over its host species showed that for three of the five analysed viruses there was a significant host association, i.e., the value of the index of selectivity for the pathogen (isp) significantly departed form zero.....interestingly, there was a positive correlation between the ish and the average virus prevalence for these 21 host plant species, showing that the more selective hosts are more prone to be virus-infected, obviously by the virus(es) that better infects them.....the relationships between prevalence and selectivity for viruses and hosts were not due to a coincidence in the frequency of infection among hosts by different viruses, as shown by a contingency analysis of counts of infected hosts by the different viruses (p,10 24 )."
"c9b4c7691175724573497c35ff6ac960a3208104","patient-clinic","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).....the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.....chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd."
"c6b4bc9d758eb2542292da9540b16861b6e1b023","patient-clinic","the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).....the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.....chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd."
"9a494f17a77c5920be077ac59abc8a7546f4ee67","patient-clinic","the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).....the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.....chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd."
"c6b4bc9d758eb2542292da9540b16861b6e1b023","patient-clinic","chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).....the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.....chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd."
"2bd481afbcdbbc5c78d67ed1f7204b09c1f83da1","patient-clinic","because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd.","the mean wbcs in the g6pd-deficient patients and the g6pd normal patients were 11.6 and 10.7 cells/ mcl respectively (p= 0.77); also, the mean neutrophil percentages in g6pddeficient patients and g6pd normal patients were 54.86% and 53% respectively (p=0.86).....the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....the objectives of this case-control study were twofold: (1) to evaluate sterilely resected lymph nodes in documented patients with sarcoidosis for the presence of bacterial dna by molecular methods and (2) to correlate the results with clinical characteristics of the patients.....chest  long  the objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial dna by molecular methods and b) correlate the results with clinical characteristics of the patients.....because prolonged fever can lead to increased in cidence of cals in patients with kd 6) , identification of patients at risk of developing ivig resistance, allowing potential early therapeutic interventions, would be beneficial for the prognosis of patients with kd."
"c7b16abf574515b631f758dc51170ef757fd58b4","mice-cell","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)....a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.....also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .....moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).....skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice."
"bb61dcfd20c7d56e90a52779d3f51a1f68c46362","mice-cell","a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)....a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.....also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .....moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).....skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice."
"953d78fb78ffe2bd8db79fac2390d45bd28a4952","mice-cell","also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)....a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.....also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .....moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).....skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice."
"953d78fb78ffe2bd8db79fac2390d45bd28a4952","mice-cell","moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)....a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.....also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .....moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).....skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice."
"953d78fb78ffe2bd8db79fac2390d45bd28a4952","mice-cell","skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice.","the difference in percentage of cd69 hi cells between naïve and infected mice was statistically significant for all subsets by t test, p = 0.0225 for cd4 + t cells, 0.003 for cd8 + t cells, and 0.0018 for cd19 + b cells (n = 2 mice per naïve group and 3 mice per infected group.)....a global decrease in liver infiltrate cell number was observed, especially for the immune cell populations of b lymphocytes, t lymphocytes, nkt cells, and macrophages in the wt mice but more importantly in the il-33 ko mice following l2-mhv3 infection.....also, the absolute number of splenic cd3 -nk1.1 + dx5 + nk cells was transiently decreased in both ccr5 +/+ and ccr5 −/− mice, but ccr5 +/+ mice had a higher number of cd3 − nk1.1 + dx5 + nk cells in the spleen at the early phase (1 and 2 dpi), compared to ccr5 −/− mice (fig. 4c) .....moreover, cd4 + t cells sorted from the cns of ccr5 +/+ mice showed higher expression of the transcription factors t-bet and foxp3, which are involved in the differentiation of cd4 + th1 cells and tregs, compared to those from the cns of ccr5 −/− mice (fig. 6e ).....skewed il-17 + cd4 + th17 responses of ccr5-ablated mice during je progression nk and cd8 + t cells did not appear to play a dominant regulatory function in already progressed je because ccr5 +/+ mice failed to show enhanced cns infiltration of nk or cd8 + t cells at 5 dpi, compared to ccr5 −/− mice."
"deea74c59b21622d228c43adea5340e8a2447081","vaccin-immun","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.....109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.....the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.....however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.....what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r)."
"ccb21efaed2edb86c05dd860b5f61beaf856e2a8","vaccin-immun","109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.....109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.....the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.....however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.....what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r)."
"2c0c7b9bdc81461fbf533ae6b89fd78326651306","vaccin-immun","the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.....109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.....the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.....however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.....what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r)."
"34277d7f5f84c871e13853e830eb07b2186f8fec","vaccin-immun","however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.....109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.....the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.....however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.....what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r)."
"8ad6fe3d0031f1dffb84dec640ac0bb7c5ba84fb","vaccin-immun","what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r).","    in addition to profiling the t-cell epitope repertoire, assessing the antigenic determinants that interact with b-cells and antibodies is of high significance in elucidating immune responses in vaccine development and vaccine design.....109 as a result, significant resources have been dedicated to the development and optimization of bvdv vaccines and vaccine protocols, considering variables such as the type and timing of vaccination on immune response and protection against challenge.....the importance of the fv-specific cd4 + t cell response for vaccine protection was emphasized by a depletion experiment, in which vaccine-mediated protection was completely abolished when cd4 + t cells were depleted around the time point of vaccination.....however, in other studies, the presence of polyfunctional t cells in either mva85a-vaccinated adults 45 or bcg-vaccinated infants 46 did not correlate with protection against tb in humans, highlighting the incomplete understanding of immune correlates of vaccine-induced tb protection.....what is more important, antibodies generated by either the mixture of vaccines (av-1959r/av-1980r) or the dual vaccine (av-1953r) recognized the same species of aβ and tau that were detected by antisera isolated from mice vaccinated with appropriate single vaccines (av-1959r and av-1980r)."
"4090c4a0e8cead64dd9e44a1610fb4f557fefdcf","viru-zikv","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .....given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.....models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).....briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.....accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) ."
"366057ee7dcf005190e239f45cdb054964e828db","viru-zikv","given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .....given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.....models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).....briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.....accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) ."
"aba0193185525dbd5c85f38245bcd05861ec4513","viru-zikv","models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .....given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.....models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).....briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.....accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) ."
"7d8b8767e12fc4fee2b29c6473b7dd1f3244b933","viru-zikv","briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .....given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.....models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).....briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.....accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) ."
"21a9444b2cd05fcac9c082ca87fac36e91086b6c","viru-zikv","accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) .","in a previous study, we prepared the zikv-e 294-302 tetramer and showed that zikv-specific cd8 + t cells exist in the brains and spinal cords of zikv-infected ifnar1 -/mice, which may have important implications for the design and development of zikv vaccines 10 .....given the total number of zikv infections ( ) and the number of asymptomatic zikv infections ( ), the probability to observe a total of household members presenting with zikv-like symptoms is the probability that − ( − ) presented with symptoms not related to zikv, among the − ( − ) members who do not presented with symptoms related to zikv.....models of zikv infection in cynomolgus monkeys have also been developed (koide et al., 2016; osuna et al., 2016) , showing that these animals are susceptible to infection to zikv isolates from cambodia and puerto rico, but not to an african zikv strain (ibh30656).....briefly, vero e6 cells (10 5 /well) or zikv were incubated at different infection steps as described below, with or without the tested natural products at the specified concentrations of 15 µm for gossypol, 30 µm for curcumin, 7.5 µm for digitonin, or 30 µm for conessine for 1 h before zikv infection, 1 h after infection, or the same time during infection.....accordingly, it was also reported that certain replication-associated structures were absent in zikv-infected human neural progenitor cells and that vesicular structures were markedly smaller than the ones observed in zikv-infected huh-7 cells (16) ."
"ef20a0cd67ce018cf061f154bd8be9d0e58d0f23","calv-calf","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).....the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).....for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).....mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).....an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property."
"ef20a0cd67ce018cf061f154bd8be9d0e58d0f23","calv-calf","the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).....the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).....for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).....mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).....an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property."
"ef20a0cd67ce018cf061f154bd8be9d0e58d0f23","calv-calf","for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).....the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).....for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).....mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).....an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property."
"ef20a0cd67ce018cf061f154bd8be9d0e58d0f23","calv-calf","mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).....the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).....for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).....mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).....an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property."
"ed91b54f1a51e6cca478909c62a47c7210a41a31","calv-calf","an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property.","when considering calves that did not receive supplementation, respective to each of the 3 groups, for at least the first five days of diarrhea there was no significant difference between either zm-and zs-treated calves compared to placebo-treated calves (p = 0.223 zm, p = 0.134 zs).....the prevalence of c. parvum fecal shedding at resolution of diarrhea was significantly higher in calves treated with zm (p = 0.009) and zs (p = 0.023) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 1.000).....for 59 calves that tested positive for rotavirus on the first day of diarrhea (table 3) , calves treated with zm had a 50% increased odds of testing negative at diarrhea resolution compared to placebo-treated calves, though this difference was not significant (p = 0.549).....mean post-treatment serum zinc concentrations were significantly higher in calves treated with zm (p < 0.001) and zs (p = 0.002) compared to placebo-treated calves, and there were no significant differences among calves treated with zm and zs (p = 0.406).....an aetiological diagnosis was not reached for all of the calves with diarrhoea due to cost constraints, the fact that it would make no difference to treatment protocol, and because most of these calves came from two farms and it was assumed that the causative agent would likely be the same in all calves from the same property."
"0d8f8313ebf345a47ae755d7f470b393a79893fe","cov-sar","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.....to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).....the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined."
"d73750cd7f032ab3f9fe5cf6f9a861c9e7567289","cov-sar","to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.....to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).....the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined."
"181b7b57851e6f58a601b68e613d10c10616f774","cov-sar","a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.....to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).....the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined."
"09de57e5401565a1e80361d32b09ce66b3a988c8","cov-sar","a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.....to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).....the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined."
"e88b28b3664d30889a0161ddee188c48897a3bee","cov-sar","the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined.","we have previously shown that the orf6 protein colocalizes with lamp1-positive vesicles in sars-cov infection (5) and also with the nsp8 protein in the same set of infected cells, indicating a possible role for the orf6 protein in the replicative process of sars-cov.....to explore whether the n-terminus of the sars-cov n protein also participates in its oligomerization, as seen for the mhv n protein, we performed pull-down experiments with recombinant 6xhis-tagged sars-cov-n1-n2a and immobilized gst-sars-cov-n1-n2a.....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) (figure 1a ).....a straightforward reference-sequence-based comparison indeed confirmed this, showing that the m, n, and e proteins of sars-cov-2 and sars-cov have over 90% genetic similarity, while that of the s protein was notably reduced (but still high) ( figure 1a ).....the 9b protein has been shown to get expressed in sars-cov-infected cells and antibodies against it have been found in the sera of sars infected patients, demonstrating that the protein is produced during infection     , but its actual function is not yet determined."
"0d5be5a4268da7c08b478ca36721d46bd67bbe69","express-cell","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).....in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.....in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.....we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .....results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells."
"cf8e39bf81b1e6e273adf55fb5db2245bd8bc885","express-cell","in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).....in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.....in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.....we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .....results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells."
"22e1dd30a5cbd30d28a4d121e4876c8e327f027e","express-cell","in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).....in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.....in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.....we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .....results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells."
"3bc70642b00cb1e53c8a6c83a584e429d626d199","express-cell","we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).....in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.....in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.....we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .....results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells."
"cf7837069ab6a12d5663c6f3c715b73fe53493a1","express-cell","results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells.","the results of this experiment showed that the anti-mir mir-141 inhibitor could cause an increase in tgf-β2 protein expression in h1n1 or h5n1 infected cells, as compared to cells only infected with h1n1 or h5n1 but without anti-mir mir-141 inhibitor treatment ( figure 3 ).....in particular, mature mir-146 and mir-155 were significantly upregulated in infected st cells compared with the control group; the fold changes of mir-146 and mir-155 between the infected st cells and the control group were 3.30 and 1.74, respectively.....in conclusion, the results of the present study provide evidence that tgev infection resulted in altered profiles of mirnas in pk-15 cells and the differentially expressed mir-4331 was involved in regulation of tgev transcription by targeting cellular cdca7.....we previously reported that tgev infection led to 21 differentially expressed mirnas, among which mir-4331 inhibited transcription of tgev gene7 via targeting cdca7  , and mir-27b functioned as a negative regulator during tgev-induced apoptosis  .....results presented here show that cellular mir-181b in f81 cells inhibits replication of mev by targeting its ns1 mrna coding region resulting in ns1 translational repression, while mev infection down regulates cellular mir-181b expression in f81 cells."
"039ca723ee32358eb70a084eaee19e1b6adc3033","avian-viru","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.....importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .....studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .....whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.....the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader."
"b3ad716630b356b1399e9df08cad73b1e92f317d","avian-viru","importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.....importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .....studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .....whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.....the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader."
"a7f47a771ace5d75afbd36064bb1a843f9821f83","avian-viru","studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.....importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .....studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .....whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.....the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader."
"d882f79283751d6c7f2e48cb991ee8abbcd913ae","avian-viru","whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.....importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .....studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .....whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.....the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader."
"8b264d2d749532dff506b14356b606029bb94035","avian-viru","the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader.","56 however, other influenza a(h5) subtypes, such as influenza a(h5n2), a(h5n3), a(h5n6) and a(h5n8), have recently been detected in birds in europe, north america, and asia, and so far no human cases of infection have been reported, with the exception of three human infections with influenza a(h5n6) virus detected in china in 2014-15.....importantly, most of the low pathogenic avian influenza (lpai) h7n9 viruses, which caused human infections in different parts of china since february of 2013  , had high viral sequence identities to the h7n9 viruses isolated from wet poultry markets  .....studies have shown that higher volumes of minor poultry sales resulted in a significant increase in virus isolation rates  , and that live poultry market density was the most important predictor of h7n9 infection risk within poultry markets  .....whilst much research and planning is currently underway to contain any outbreak in humans, relatively little is known about the extent of infection in poultry and, in particular, the transmissibility of highly pathogenic avian influenzas between poultry farms.....the primary limitation to our study was that poultry and poul- in conclusion, we have identified poultry trade practices that impact the risk of influenza virus a infection in chickens, and we have been able to attribute these practices to certain types of poultry trader."
"2739ea989ec040104223cfb49d2a13d7d89dc79a","gene-express","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.....assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .....assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .....these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.....thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study."
"bbfbefd19c9c471dbacabd1f57124d1ad36f24f5","gene-express","assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.....assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .....assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .....these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.....thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study."
"43eaa4d7209e389a360aeab2b3b44e76fd89f5c2","gene-express","assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.....assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .....assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .....these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.....thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study."
"69d2e69e949dab8909be8c7b764a0d5469546b31","gene-express","these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.....assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .....assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .....these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.....thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study."
"222f2de4774452963b9c8b640faf80dced073b64","gene-express","thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study.","those internal control genes, also known as reference genes, are often referred to as housekeeping genes, assuming that those genes are expressed at a constant level in certain tissues, at all stages of development and are unaffected by the experimental treatment.....assuming that the reference genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed reference genes that have the most stable expression in the tested samples (vandesompele et al., 2002) .....assuming that the control genes are not co-regulated, stepwise exclusion of the gene with the highest m value results in a combination of two constitutively expressed housekeeping genes that have the most stable expression in the tested samples  .....these reference genes can be generally classified into several groups: transcription-related genes (ef1α), structure/ cytoskeleton-related genes (tub1), protein synthesisrelated genes (rpl2a, rpl10, and rpl13a), and finally, genes that cannot be clearly categorized, including ppia and sdha.....thus, it is now recommended to use these genes only as reference genes for normalization when prior analysis of their expression stability has been carried out  , to ensure that cellular expression level of the reference genes is virtually identical under different conditions in the study."
"b28a8c489742fd2227e6e4049d777febfd4051cc","epitop-bind","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .....this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.....in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.....this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .....to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers."
"f9162c1be900c7bab2cc52de3e8cdef666c4824c","epitop-bind","this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .....this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.....in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.....this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .....to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers."
"31b6292728805572de28133c6eb02ed1d44ef211","epitop-bind","in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .....this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.....in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.....this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .....to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers."
"5076cec908e9bc3ba685507e00ac19deab50b02e","epitop-bind","this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .....this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.....in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.....this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .....to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers."
"2ebf1526911eca26db1a7933e592260302caa3b7","epitop-bind","to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers.","hpv01 (consisting of hpv16-e7 82−94 and hpv16-e6 41−65 ) and hpv08 (hpv16-e7 69−93 ) are long peptide antigens which both include the cd8 + t cell epitope hpv05 (hpv16-e7 86−93 ), but in a different surrounding amino acid context, by including different cd4 + t epitopes into their sequence ( table 2) .....this was done considering highest blosum scores of the epitopes in which the epitopes were more similar than non-epitopes; conversely, in the case where the non-epitope were more similar than the epitopes the highest blosum scores of the non-epitopes was considered.....in our analysis, we observed that, though all the residues in the input peptide sequences were not present in the epitope binding sites, a highest scoring patch correctly predicted the location of the conformational epitopes as found in the crystal structure.....this strategy allows to define specific epitopic and non-epitopic patterns that are then applied to the local amino acid composition of the antigen; prediction is thus performed without considering the whole protein sequence but searching for epitopic patterns  .....to analyze the location of the vp3 epitope in relation to previously identified ev71 epitopes (the linear neutralizing epitope kqekd of mab 51 on vp1, and the linear epitope edshp of mab 7c7 on vp2) [30, 37] , we studied stereographic images of ev71 protomers."
"25a348f34236403317091db876b29fd5063528ed","pandem-health","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""....even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.....with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.....overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.....furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza."
"a699cfdfda9ccc5ccb41e946a63113106b39148d","pandem-health","even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""....even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.....with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.....overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.....furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza."
"a699cfdfda9ccc5ccb41e946a63113106b39148d","pandem-health","with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""....even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.....with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.....overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.....furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza."
"16627f4c7134394da448b1417a771d13ad7cca4a","pandem-health","overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""....even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.....with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.....overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.....furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza."
"25a348f34236403317091db876b29fd5063528ed","pandem-health","furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza.","the need for help with planning for pandemic influenza, which can be considered an indicator of an adaptive response to the threat of pandemic influenza, was assessed using the following open-ended question: ""is there anything you need to help you prepare for pandemic influenza?""....even though individuals with poor self-rated health believed that pandemic influenza was more likely to occur and felt more concern for self and family in the case of a pandemic influenza than those with good self-rated health, they were not more likely to report changing their life as a result of the possibility of pandemic influenza.....with previous influenza pandemics and the current h1n1 influenza pandemic arriving with little to no warning, we are afforded a unique opportunity to prepare for the next pandemic threat, which has the potential to be more severe than the current pandemic.....overall 14.9% of the population thought pandemic influenza was very or extremely likely, 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza, and 23.8% had made some (small to extreme) level of change to the way they live their life because of the possibility of pandemic influenza.....furthermore, our finding that the need for help was not significantly related to whether a plan for pandemic influenza exists appears to highlight the difficulties associated with planning for pandemic influenza, even among those businesses that have already made specific plans for pandemic influenza."
"6328beb961554b05276359e9c5b26d2e57cd52e9","cell-protein","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .....the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .....this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.....this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.....rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) ."
"6328beb961554b05276359e9c5b26d2e57cd52e9","cell-protein","the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .....the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .....this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.....this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.....rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) ."
"ea6c3d35646adfcd7e1c55d7d1f0998ba1107d89","cell-protein","this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .....the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .....this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.....this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.....rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) ."
"05b5ca303bd262f2a8e7d9d05d203f023867d0ed","cell-protein","this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .....the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .....this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.....this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.....rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) ."
"955a11ffa21e8ea71e2dd4ed9b59ebc6a8990535","cell-protein","rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) .","in the earlier experiments it was found that substitution of two to three uncharged amino acids for the normal cytoplasmic domain of g protein (mutant 1473h 1) resulted in a g protein that accumulated in the rough er and golgi membranes, but not on the cell surface (47) .....the journal of cell biology, volume 102, 1986 2154 the transport of membrane and secretory proteins to the cell surface is thought to occur along the same basic pathway from the er, through the three to four compartments of the golgi complex to the cell surface (51) .....this gives us confidence that some, if not all, of the novel proteins novel proteins depleted from nucleolus on infection-of those proteins examined that show a clear nucleolar localization in uninfected cells, all had a dramatic redistribution in infected cells.....this observation, which contrasts with studies in mammalian cells demonstrating that several golgi membrane proteins are retained via their transmembrane domains (machamer, 1991) , indicates that golgi retention signals can reside in cytoplasmic or transmembrane domains.....rsp5 is an essential protein, so it would have been absent from our screen, but the rsp5 adaptor proteins bsd2 and tre1, which regulate the trafficking and stability of plasma membrane and golgi proteins, were identified (portnoy et al., 2000; hettema et al., 2004; stimpson et al., 2006) ."
"babad3896fca8ed7c89d9b785c08e7c42a48a6a2","respiratori-exacerb","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .....it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.....also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.....patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .....results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively."
"40886c8a1c173dab7ef1685c544a7554f63bd6ff","respiratori-exacerb","it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .....it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.....also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.....patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .....results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively."
"1829dd66176c20fb22a9d7186d62fa596cc93f9c","respiratori-exacerb","also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .....it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.....also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.....patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .....results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively."
"e14d8123b56a1b4825bf8aa262ff4f4d0f9549b4","respiratori-exacerb","patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .....it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.....also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.....patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .....results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively."
"a5293bb4f17ad25a72133cdd9eee8748dd6a4b8d","respiratori-exacerb","results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively.","some published studies have stratified copd patients on the basis of exacerbation frequency; this is generally done by categorising patients as having either 'infrequent' or 'frequent' exacerbations if they had less than or greater than a mean of three exacerbations per year, respectively  .....it has also been recognized that some patients with copd are particularly susceptible to exacerbations and these patients have been termed 'frequent exacerbators' , in contrast to patients with infrequent exacerbations who experience few exacerbations over time.....also, patients with asthma who had an exacerbation following experimental infection had higher levels of viral rna in their sputum compared to asthmatics that did not experience an exacerbation, further evidence that viruses do indeed cause exacerbations.....patients with asthma-copd overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with copd alone 61 .....results: patients in ccp-childhood asthma at smich were enrolled from 81 children in year 2012 to 119 children in year 2014, the number of hospitalization from asthma exacerbation was decreased from 24 patients in year 2012 to 20 and 13 patients in year 2013 and 2014, respectively."
"88c599b1de8a17cd519f9f72aaaea28392f697f0","activ-protein","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.....5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.....as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.....in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .....the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) ."
"8812b0579ea75d59a8dca6407431a3f716728556","activ-protein","5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.....5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.....as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.....in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .....the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) ."
"5ae7223cc6ab3437ba262bb2bb47768948e01d59","activ-protein","as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.....5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.....as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.....in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .....the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) ."
"0f06fc59914545bf3fdd7ae0b2cd8fe2a4208ace","activ-protein","in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.....5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.....as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.....in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .....the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) ."
"32d5699f514f8d58fa7939fefaea6ef9fce1121c","activ-protein","the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) .","since hsp70, which is translated in 5 -cap independent mechanism, is also up-regulated in the cells infected with cvb3 , we presumed that the increased expression of hsp70 could be responsible for the dysregulated cell cycle control proteins in the cells expressing vp1.....5a , grp78 and grp94 increased only in cells expressing gp (the full-length glycoprotein, containing both gn and gc) or cells treated with tunicamycin (tm), a reported inducer of the upr, but not in cells expressing other viral proteins, including np, nss, and rdrp, or the control gfp.....as the result, only 5% and 24% of cells reached g1 by 2 and 4 hours, even though by 8 hours most of pul21a-expressing cells were able to enter g1, likely due to low expression of pul21a in these cells as compared to those in transiently transfected cells.....in sa treated cells, nanog and l1td1 are the only pluripotent protein markers that were significantly decreased compared to nontreated cells, whereas in cells subjected to 42˚c, the expression of all other pluripotent protein markers was significantly decreased (fig 4b and 4c) .....the expression of c-gsdma3 and c-gsdma3 rim3 induced very little late apoptosis (annexin v + 7aad + ), and gsdma3-expressing cells (16.4 ± 6.1 %), n-gsdma3-expressing cells (29.6 ± 7.2 %), and gsdma3 rim3 -expressing cells (60.5 ± 9.9 %) displayed higher level of late apoptosis staining than c-gsdma3-expressing cells (p < 0.005) (fig. 2b) ."
"4ef4cb3ed4814b1afceebb92b410e53fd5646f4e","ifitm-cell","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.....in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .....to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).....ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .....given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig."
"4b55b2415bd2adff96e6013f792d281693bf4587","ifitm-cell","in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.....in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .....to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).....ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .....given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig."
"4ef4cb3ed4814b1afceebb92b410e53fd5646f4e","ifitm-cell","to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.....in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .....to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).....ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .....given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig."
"4ef4cb3ed4814b1afceebb92b410e53fd5646f4e","ifitm-cell","ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.....in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .....to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).....ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .....given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig."
"34e218f77932d4c7a4c29c7a18010d846ee3f4a6","ifitm-cell","given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig.","in the work presented here we describe a novel feature related to the biology of ifitms, namely their ability to be figure 6 ifitms incorporation into hiv-1 viral particles affects viral infectivity by interfering with entry of the virus in target cells.....in fact, a recent study suggested that blockade of viral entry by ifitm proteins might be a multifaceted process, because ifitm proteins were shown to be incorporated into the retroviral envelope thereby reducing infectivity of progeny virions  .....to determine at which step the incorporation of ifitms affected viral infectivity, virion particles produced in presence or absence of ifitms were purified and normalized as described above and used to challenge target cells according to two methods (schematically indicated in figure 6a ).....ifitm proteins are incorporated onto hiv-1 virion particles and negatively imprint their infectivity the interferon-induced transmembrane proteins (ifitms) are a family of highly related proteins composed of 5 members in humans (ifitm1, −2, −3, −5 and −10) [1, 2] .....given the function significance of ifitm family deletion on the transcriptome of resting cd4 + t cells, we next investigated ifitm expression in facs-sorted naïve wt cd4 + t cells by rna sequencing, after anti-cd3/cd28 activation over a longer 30-h time course ( fig."
"433adf76ea9adc9f5c540d4c28142d4d020969e2","cell-induc","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).....in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).....epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .....the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.....several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     ."
"c8a84384011fca6e1e24511d1b053eef4650fc04","cell-induc","in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).....in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).....epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .....the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.....several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     ."
"3d9b665ff94e800c03f3051567312a3921a76e81","cell-induc","epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).....in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).....epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .....the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.....several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     ."
"844b876f1636f5d031fe856cd7a63ae5f5c11fe7","cell-induc","the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).....in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).....epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .....the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.....several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     ."
"8aca747989e024abacecae2fcc95186972c3f5df","cell-induc","several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     .","these quantitative immune cell shifts appear limited to neutrophils as the proportion of ly6g lo ly6c hi inflammatory monocytes, b cells, as well as cd4 + and cd8 + t cells did not differ significantly among antibiotic treated compared with control mice (supplementary figure s1 ).....in (b) the lungs were removed at 72h of infection for the bacterial counts. n = 10 for m90t-infected-mice and n = 11 for m90t-infected and treated-mice, respectively; n = 10 for non-infected ptx3-treated mice data show total cfu per lung (cfu in one lung).....epithelial cells are not the primary targets of hantaviruses and are thus unlikely to be expressing vegf as a result of direct infection, but expression could be induced by inflammatory cytokines produced by other cells during infection or by hypoxia caused during hps (103) .....the similarity between the levels of many proteins in the kofa mice to those seen in wto 3 mice (in other words, baseline levels in the ko mice corresponded to levels induced by oxidative stress in the wt mice) led us to propose the following scenario.....several studies have demonstrated that besides the th17 cells, modulating the activities of other immune cells (e.g. macrophages, monocytes, b cells, dendritic cells, treg cells) may also be a potential therapeutic approach in ra management     ."
"99f61ec3a18d65b10e7df69531368c3afae01e45","cell-effect","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .....21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.....the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.....dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.....therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests."
"570064e6a308ec28efcc76ef74ba3f0e6ea5e5a5","cell-effect","21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .....21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.....the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.....dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.....therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests."
"9c438a13c9083e842b860ae7b477e671e60fb4cb","cell-effect","the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .....21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.....the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.....dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.....therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests."
"f223f427cbdd077ec84931fad74fb3a7a46fbc67","cell-effect","dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .....21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.....the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.....dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.....therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests."
"9c438a13c9083e842b860ae7b477e671e60fb4cb","cell-effect","therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests.","the results indicate that eckol had the highest activity against the selected cancer cell lines: hela cells, h157, and mcf7, making it a good candidate with prominent inhibitory activity against metastasis that could effectively reduce cell damage  .....21 in t-cell activation, sdpp-4  can activate t-cell proliferation via co-stimulation  with t-cell receptor (tcr) signaling and toll-like receptor, whose activation is neither associated with its enzymatic activity nor with adenosine deaminase binding.....the results of this study not only indicated the potential and/or the advantages for the effective utilization of artesunate and artemisinin in medical fields, but also demonstrated novel pharmacological activity/effects and biological actions/functions regarding the anti-mtb activity/effects.....dpp4 on antigen presenting cells, including macrophages and dendritic cells, facilitated t cell proliferation and activation through its noncatalytic activity as catalytic inhibition of dpp4 or addition of exogenous sdpp4 did not affect their capability to stimulate t cells.....therefore, these results obviously show that the compounds do not induce or cause toxicity and side effects when they indicate selective anti-mtb activities/effects, or inhibit the growth/proliferation of mtb through their novel pharmacological effects/action in in vivo tests."
"df62b9ff3b2b95896d4b90ccefc9f3d756be1abf","pneumonia-respiratori","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .....secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.....bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.....risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .....m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia."
"62a67d1f86138972ae0d79681ddd2a4a75f6dec0","pneumonia-respiratori","secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .....secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.....bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.....risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .....m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia."
"24ec3df6486c04e0eb67d213475f3f1b20fe9fec","pneumonia-respiratori","bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .....secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.....bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.....risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .....m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia."
"b04c8cddba2dfb4f953daac916d936924976392d","pneumonia-respiratori","risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .....secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.....bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.....risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .....m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia."
"e18f75d74176ea6eff4a4e8ef6ad0a0836a92a5e","pneumonia-respiratori","m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia.","as reported by several studies, the number of annual pneumonia patients in china is ≤21 million individuals, and among the children with pneumonia, 7-13% cases are of severe pneumonia, which ranks fifth amongst various diseases leading to death (11) (12) (13) (14) (15) (16) .....secondary objectives of the present study were to assess the possible association between acute symptomatic m. pneumoniae infection and children's age, and to determine the influence of m. pneumoniae genotype as well as viral and bacterial co-infections on the severity of m. pneumoniae rtis.....bacteria such as streptococcus pneumoniae, and haemophilus influenzae, and mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila, which are classified as causative bacteria of atypical pneumonia, and respiratory bacteria can cause pneumonia.....risk factors of 90-day rehospitalization following discharge of pediatric patients hospitalized with mycoplasma pneumoniae pneumonia readmission of patients initially hospitalized for community acquired pneumonia (cap) is relatively common    .....m. pneumoniae also affect infants and young children in epidemic periods, and we believe that m. pneumoniae must be considered as a differential diagnosis to respiratory virus infections and as a cause of infant and childhood troublesome lung symptoms and pneumonia."
